Transcript Slide 1

Thomas John, MD (1)
Ami A. Shah, BS MBB (2)
(1) Clinical
Associate Professor, Loyola University at
Chicago, Maywood, Illinois, USA
(2) Rosalind Franklin University of Medicine &
Science/Chicago Medical School, North Chicago,
Illinois, USA
[email protected]
• Prospective, open-label study
• 150 eyes (75 patients) with clinical chronic mixed anterior blepharitis
• Average age of patients was 65.7 years + 1.86
•Patients were treated for either 4 or 8 weeks
•33 males and 42 females
•At the initial visit, all patients underwent a complete slit-lamp examination and the
eyelids were evaluated
• Lids were evaluated for lid closure and blink patterns, apposition of eyelids, lid
inflammation, and changes or disorders of the lid margin
•Patients were instructed to apply azithromycin ophthalmic solution on to their washed,
clean index finger or to a clean applicator and then to apply the medication directly to
the eyelids of both eyes, rather than using eye drops directly onto the ocular surface OU
QHS
•Both eyes of each patient were treated with azithromycin ophthalmic solution (AzaSite®
1%, Inspire Pharmaceuticals, Durham, NC) or erythromycin ophthalmic ointment
• These patients were evaluated and treated with:
•Azithromycin (67 patients, n=134 eyes)
•Erythromycin (8 patients, n=16)
Grading of Chronic Mixed Anterior Blepharitis
Grade
Collarettes
(Height in
mm)
Ulcerations
(Percentage
of Lid
Margin)
Matting
Erythema
(Percentage
of Lid
Margin)
1 (Trace)
<1
10
0
< 25
2 (Mild)
1
30
0–5
25 – 50
3 (Moderate)
2
50
6 – 10
50 – 75
>2
>50
> 10
> 75
4 (Severe)
Any three criteria/ Upper or Lower Lid
Mixed = Seborrhic and Staphylococcal
Patients with clinical resolution
were graded 0
Clinical Resolution by 4 weeks
The total clinical resolution after 4 weeks was 98.5% for the AzaSite®
treated group and 37.5% for the erythromycin treated group
% of Patients
100
Azithromycin
Erythromycin
75
50
25
0
Azithromycin
Erythromycin
Clinical Resolution by 8 weeks
The total clinical resolution after 8 weeks was 98.5% for the AzaSite®
treated group and 50% for the erythromycin treated group
% of Patients
100
Azithromycin
Erythromycin
75
50
25
0
Azithromycin
Erythromycin
In summary, this is the first study
showing the clinical efficacy of using
azithromycin ophthalmic solution
(AzaSite® 1%, Inspire Pharmaceuticals,
Durham, NC) directly on the eyelids for
the effective treatment of chronic,
mixed, anterior Blepharitis, with
treatment times as short as 4 weeks